Alerity Therapeutics Announces Presentation Of New Data Analyses From The Phase 2 Trial Of ATH434, Demonstrating Clinical Efficacy In Patients With Multiple System Atrophy At The American Academy of Neurology Annual Meeting

- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -

- Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Part I -

- Presentation reinforces ATH434's clinical profile ahead of Phase 3 engagement with regulators -